BMY: Bullish Catalysts vs. Policy Risk - Wait for Margin Evidence

What happened

A Seeking Alpha article reiterates a Strong Buy on Bristol Myers Squibb, highlighting the Growth Portfolio's 16% revenue growth and upcoming FDA decisions for iberdomide. However, the DeepValue report maintains a WAIT rating, emphasizing that 2026 is a critical bridge year with policy-driven risks: Eliquis faces IRA price resets and a Medicaid free-supply agreement effective January 1, 2026, while Revlimid erosion accelerates after volume caps lift on January 31, 2026. The key validation point is whether Eliquis can deliver its guided 10-15% growth while keeping consolidated non-GAAP gross margin at 69-70%, as margin compression would signal growth is bought via concessions rather than durable demand. The article's optimism on pipeline catalysts is acknowledged but does not alter the near-term margin uncertainty. The market narrative is shifting toward execution proof points, but filings show date-certain policy fragilities that could undermine the bridge year.

Implication

The bullish thesis hinges on Eliquis delivering 10-15% growth without margin compression. Our analysis suggests waiting for observable proof in Q1/Q2 2026 that gross margin stays at 69-70%. If confirmed, the base case of $65 is achievable. However, gross margin below 69% would trigger a de-rating toward the bear case of $52. Pipeline readouts in 2H26 add optionality but are not the near-term driver.

Thesis delta

The DeepValue thesis maintains a WAIT rating, emphasizing the need for observable proof of Eliquis margin stability before committing. The news article's strong buy ignores the margin fragility we highlight, but the growth portfolio's momentum slightly increases the probability of base-case outcomes if policy risks are managed. Our conviction remains 3.5/5 until Q2 2026 data validates the bridge year economics.